Webinar Date: June 9, 2020 1:00 pm
Pharmacogenetics and pharmacogenomics (PGx) are trending as important fields for targeting correct therapies. Pharmacogenomics testing is an important tool to ensure a personalized approach to medication use not only today but in the future.
It makes sense that evaluation of a patient’s genotype can support the clinical decision-making process, improving patient outcomes. So, why are advances made at the bench not reaching the bedside? What are the barriers we need to overcome? Further, how do we incorporate PGx into team-based care, and how can PGx aid in treatment decisions for COVID-19 patients? This webinar will explore PGx with overviews from two recently published articles.
Hear from a clinical pharmacist and a research consultant as they discuss findings from two separate research studies on pharmacogenomics. Colleen Keenan, a consultant with The Advisory Board’s Clinical Innovators Council, will share findings from her recent paper, “Considering pharmacogenomics during COVID-19? Here’s what you need to know.” And Emily J. Cicali, Pharm.D., BCPS, clinical associate professor at the University of Florida, College of Pharmacy, shares highlights from her recent PCORI-funded publication, “Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings.”
Some of the questions we’ll address include:
- How are PGx practice activities implemented and impacted during COVID-19?
- In the post-pandemic environment, what will likely be the realities of team-based, person-centered care using PGx as a tool to support CMM?
- What are the barriers to implementation of PGx in team-based care in an ambulatory care setting?
- What are important process-of-care lessons learned during COVID-19?
- How will lessons learned from implementing team-based PGx in ambulatory care settings help shape future PGx clinical trials and clinical implementations?
- And more…
